N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
4/2/2013 9:25:21 AM
More...
|
N30 Pharma Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
3/13/2013 9:46:18 AM
More...
|
N30 Pharma Names Sherif Gabriel, Ph.D. as Vice President of Research
10/8/2012 10:11:22 AM
More...
|
N30 Pharma Announces Publication of S-Nitrosoglutathione Reductase Small Molecule Inhibitor Chemistry and Development
3/14/2011 8:21:49 AM
More...
|
N30 Pharma to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
3/2/2011 10:13:21 AM
More...
|
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
9/8/2010 11:51:59 AM
More...
|
N30 Pharma Announces FDA Approval to Initiate Phase 1 Clinical Trial for First-in-Class Drug
8/2/2010 6:55:23 AM
More...
|
N30 Pharma Announces Financing and Addition to Board
5/12/2010 9:10:57 AM
More...
|
N30 Pharma Forms Scientific Advisory Board
4/6/2009 11:18:18 AM
More...
|
Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
3/23/2009 12:01:57 PM
More...
|
|